Longeveron Rallies 20% In Morning Trade

On:

Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.

Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).

The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.

LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Analyst Predicts Bitcoin Boom Due to U.S. Debt, Money Debasement, and Global Trends
  2. Ethereum: Crypto Analyst Explains Why ‘$600 ETH Is Potentially in the Cards’
  3. MSC Industrial Direct Co. Shares Up 3% On Upbeat Q2 Results
  4. Bitcoin Futures Soar on Deribit and CME
  5. Cryptos Firm As The Dollar Retreats